Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Pfizer Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.85, while Pfizer Inc trades at $25.09 (market cap $141.46B). The key difference: Pfizer Inc pays a 6.93% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| GSG | PFE | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $34.77 | $28.56 |
52-Week Low | $22.06 | $23.29 |
Market Cap | — | $141.46B |
Volume | — | 29,869,932 |
Enterprise Value | — | $192.12B |
Dividend Yield | — | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $31.00, up 1.57% today, with strong bullish technical signals from moving averages and ADX indicators, though RSI levels suggest overbought conditions. The stock's support and resistance levels are consolidated at $31.00, indicating a pivotal price point. Recent news highlights commodities as a key market theme, which may benefit GSG given its focus.
The outlook for GSG is cautiously optimistic, driven by bullish technical trends and positive sentiment around commodities. Risks include potential overbought corrections and reliance on commodity market stability. Investment opportunities hinge on sustained commodity demand, but investors should monitor earnings fundamentals for validation.
Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.
Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
